Literature DB >> 26108526

Baseline haemoglobin A1c influences retinal function after long-term insulin pump therapy.

Oliver N Klefter1,2, Stig K Holfort3, Michael Larsen3,4.   

Abstract

PURPOSE: The purpose of the study was to characterize the long-term effect of insulin pump therapy (CSII) on electroretinography and dark adaptometry and to examine the influence of baseline glycaemic control on retinal function in patients with type 1 diabetes mellitus.
METHODS: This prospective observational extension study enrolled 13 patients out of 17 who completed a primary 1-year study of the effect of CSII on retinal function. Twelve patients were still on CSII at follow-up. The extension study included a single examination 3.5 years (range 3.0-4.0 years) after initiation of CSII of one study eye per patient. Procedures included full-field electroretinography (ERG), dark adaptometry, optical coherence tomography, and fundus photography.
RESULTS: Mean ERG amplitudes 3.5 years after initiation of CSII were 15-43 % lower than at baseline (all p < 0.05) and 21-45 % lower than after 1 year on CSII. The mean rate of dark adaptation had returned to baseline after a transient 13 % (p = 0.0024) acceleration at the 1-year visit. Reduction of ERG amplitudes between 1 and 3.5 years was statistically associated predominantly with baseline haemoglobin A1c (HbA1c) ≥ 8.7 % and, to a smaller extent, with HbA1c reductions larger than 1.9 % after initiation of CSII. No significant changes in ERG amplitudes were found in patients with baseline HbA1c < 8.7 % and HbA1c reductions smaller than 1.9 %.
CONCLUSIONS: Deterioration of subclinical retinal function from 1 to 3.5 years after initiation of CSII was associated predominantly with poorer metabolic control before initiation of CSII. Analyses of retinal function may supplement structural and morphological characteristics in the study of diabetic complications.

Entities:  

Keywords:  Dark adaptation; Diabetes mellitus; Diabetic retinopathy; Electroretinography; Insulin pump; Retina

Mesh:

Substances:

Year:  2015        PMID: 26108526     DOI: 10.1007/s00417-015-3083-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  28 in total

1.  ISCEV Standard for full-field clinical electroretinography (2008 update).

Authors:  M F Marmor; A B Fulton; G E Holder; Y Miyake; M Brigell; M Bach
Journal:  Doc Ophthalmol       Date:  2008-11-22       Impact factor: 2.379

2.  Differential changes in retina function with normal aging in humans.

Authors:  Paul R Freund; Juliane Watson; Gregory S Gilmour; Frédéric Gaillard; Yves Sauvé
Journal:  Doc Ophthalmol       Date:  2011-05-12       Impact factor: 2.379

3.  The electroretinogram in diabetic retinopathy. A clinical study and a critical survey.

Authors:  M Gjötterberg
Journal:  Acta Ophthalmol (Copenh)       Date:  1974

4.  Oscillatory potentials, macular recovery time, and diabetic retinopathy through 3 years of intensified insulin treatment.

Authors:  O Brinchmann-Hansen; K Dahl-Jørgensen; K F Hanssen; L Sandvik
Journal:  Ophthalmology       Date:  1988-10       Impact factor: 12.079

5.  Inner retinal visual dysfunction is a sensitive marker of non-proliferative diabetic retinopathy.

Authors:  Gregory R Jackson; Ingrid U Scott; David A Quillen; Laura E Walter; Thomas W Gardner
Journal:  Br J Ophthalmol       Date:  2011-12-15       Impact factor: 4.638

6.  Macular recovery time, diabetic retinopathy, and clinical variables after 7 years of improved glycemic control.

Authors:  O Brinchmann-Hansen; K Dahl-Jørgensen; K F Hanssen; L Sandvik
Journal:  Acta Ophthalmol (Copenh)       Date:  1992-04

7.  Nonselective loss of contrast sensitivity in visual system testing in early type I diabetes.

Authors:  M A Di Leo; S Caputo; B Falsini; V Porciatti; A Minnella; A V Greco; G Ghirlanda
Journal:  Diabetes Care       Date:  1992-05       Impact factor: 19.112

8.  A short-duration dark adaptation protocol for assessment of age-related maculopathy.

Authors:  Gregory R Jackson; John G Edwards
Journal:  J Ocul Biol Dis Infor       Date:  2008-05-06

9.  A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial.

Authors:  Eric S Kilpatrick; Alan S Rigby; Stephen L Atkin
Journal:  Diabetes Care       Date:  2008-07-23       Impact factor: 17.152

10.  Impact of changes in metabolic control on progression to photocoagulation for clinically significant macular oedema: a 20 year study of type 1 diabetes.

Authors:  B Sander; M Larsen; E W Andersen; H Lund-Andersen
Journal:  Diabetologia       Date:  2013-08-30       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.